Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

A Study of Zanubrutinib Versus Tacrolimus in Participants With Primary Membranous Nephropathy (ALMOND) Recruiting

2022-501147-32-00 Primary Membranous Nephropathy 10 2024-07-11
A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting

2023-503904-10-00 Sjögren’s Syndrome With Moderate-to-severe Systemic Dis 5 2024-06-07
Trial of efficacy and safety of NS-229 versus placebo in patients with Eosinophilic Granulomatosis With Polyangiitis Recruiting

2023-504245-32-00 Eosinophilic granulomatosis with polyangiitis (EGPA) 4 2024-06-06
Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis… Recruiting

2022-502050-14-00 Crohn's disease 5 2024-06-04
A clinical study to assess if a new investigational medicinal product called JJP-1212 is safe, tolerable and able to induce a specific immun… Recruiting

2023-508661-33-00 Rheumatoid Arthritis 1 2024-05-29
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4) Recruiting

2023-507067-19-00 Autoimmune Cytopenias (warm autoimmune hemolytic anemia 4 2024-05-15
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Moderate to Severe Plaque Psoriasis 5 2024-03-22
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and how Drug Move… Recruiting

2022-501599-25-00 juvenile idiopathic arthritis 5 2024-03-19
Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neona… Recruiting

2023-504307-88-00 Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) 5 2024-02-20
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting

2022-502739-20-00 Active Idiopathic Inflammatory Myopathies (Including De 5 2023-11-16
Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post acute covid and immune system activation: t… Recruiting

2023-508123-12-00 Post-Acute COVID Syndrome (PACS) 10 2023-11-03
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome Recruiting

2023-505140-19-00 Childhood Idiopathic Nephrotic Syndrome 5 2023-07-31
A Phase 2 Study on Narsoplimab in Paediatric Patients with High Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy Recruiting

2023-509710-11-00 Haematopoietic Stem Cell Transplant Thrombotic Microang 4 2023-07-11
A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease Recruiting

2022-500718-24-00 IgG4-Related Disease 5 2023-06-09
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Recruiting

2022-501427-24-00 Nonadvanced Systemic Mastocytosis 4 2023-04-25
A Study of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with R/R PTCL Recruiting

2022-500391-62-00 Subjects with relapsed/refractory peripheral T-cell lym 9 2023-01-19
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
An extension phase 2/3 study to test the safety of long term administration of oral PHA-022121 for acute treatment of angioedema attacks in … Recruiting

2023-505766-28-00 Hereditary angioedema 10 2022-10-10
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Subcutaneously in Children With Generalized Myasthenia Gravis (AD… Recruiting

2023-507379-23-00 Generalized Myasthenia Gravis 10 2022-08-18
BIVV020 (SAR445088) in prevention and treatment of antibody-mediated rejection (AMR) Recruiting

2023-509936-25-00 Transplant Rejection 4 2022-06-09
Study of efficacy and safety of iptacopan in complement 3 glomerulopathy patients Recruiting

2023-509331-83-00 complement 3 glomerulopathy 5 2021-07-28
Phase I/II clinical trial of autologous hematopoietic stem cell gene therapy in rag1-deficient severe combined immunodeficiency Recruiting

2023-510204-50-00 Severe combined immunodeficiency based on genetic defec 3 2021-07-23
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and the… Recruiting

2022-501677-39-00 Adolescent Renal Allografts 5 2021-05-25